# OnCo record nct06820463 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06820463/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06820463", "NCT06820463" ;
  schema:name "A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,"@en ;
  schema:alternateName "AndroMETa-CRC"@en ;
  schema:description "A phase 2 trial of Telisotuzumab adizutecan, Fluorouracil, CAPOX in colorectal cancer, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06820463/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06820463> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-04-24" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/panitumumab/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .